Advertisement


Aaron Goodman, MD, on Immune Checkpoint Blockade: Clinical Implications

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Aaron Goodman, MD, of the University of California, San Diego School of Medicine, discusses an analysis of more than 100,000 patients with cancer for CD274 (PD-L1) amplification and the implications for treatment with immune checkpoint blockade (Abstract 47).



Related Videos

Kidney Cancer
Immunotherapy

Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments

Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging...

Prostate Cancer
Immunotherapy

James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options

James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inh...

Immunotherapy

Ann W. Silk, MD, and Katy K. Tsai, MD: Meeting Highlights

Ann W. Silk, MD, of the Rutgers Cancer Institute of New Jersey, and Katy K. Tsai, MD, of the University of California, San Francisco, who are Co-Chairs of the Clin...

Lung Cancer
Immunotherapy

Roy S. Herbst, MD, PhD, on Personalized Immunotherapy for Lung Cancer: Expert Perspective

Roy S. Herbst, MD, PhD, of the Yale School of Medicine, summarizes a session that included discussion of the mechanisms of immunotherapies, biomarkers for activity of these agents,...

Issues in Oncology
Immunotherapy

Mary L. Disis, MD, on Basics of Immunology: An Overview

Mary L. Disis, MD, of the University of Washington, discusses innate and adaptive immune system cells, T cells as key to mediating antitumor immunity, and the mechanisms by which c...

Advertisement

Advertisement



;
Advertisement